A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female participants, homozygous for the F508del CFTR mutation
Confirmed diagnosis of CF by sweat chloride testing
Forced Expiratory Volume in 1 Second (FEV1) ≥40% and ≤90% of predicted normal for age, sex, and height at Screening Visit
Stable CF disease as judged by the investigator.
You may not be if
History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1
History or evidence of clinically significant findings on ophthalmologic examination during the Screening Period.
History of solid organ or hematological transplantation
Pregnant or nursing females
Participants who have had radiation exposure within 1 year before the first mucociliary clearance (MCC) procedure that would cause them to exceed federal regulations by participating in this study
In the opinion of the investigator, unable to adequately perform inhalation maneuvers during the MCC procedures